New York State Common Retirement Fund decreased its holdings in Advaxis, Inc. (NASDAQ:ADXS) by 0.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 34,200 shares of the biotechnology company’s stock after selling 1 shares during the quarter. New York State Common Retirement Fund owned 0.08% of Advaxis worth $222,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. PNC Financial Services Group Inc. lifted its position in Advaxis by 18.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 26,000 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 4,000 shares in the last quarter. TIAA CREF Investment Management LLC lifted its position in Advaxis by 2.4% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 98,164 shares of the biotechnology company’s stock valued at $637,000 after acquiring an additional 2,329 shares in the last quarter. Teachers Advisors LLC lifted its position in Advaxis by 5.1% in the 2nd quarter. Teachers Advisors LLC now owns 69,428 shares of the biotechnology company’s stock valued at $451,000 after acquiring an additional 3,369 shares in the last quarter. Alliancebernstein L.P. lifted its position in Advaxis by 44.8% in the 2nd quarter. Alliancebernstein L.P. now owns 67,900 shares of the biotechnology company’s stock valued at $441,000 after acquiring an additional 21,000 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its position in Advaxis by 2.6% in the 2nd quarter. Wells Fargo & Company MN now owns 44,813 shares of the biotechnology company’s stock valued at $290,000 after acquiring an additional 1,144 shares in the last quarter. 44.07% of the stock is currently owned by institutional investors and hedge funds.
Shares of Advaxis, Inc. (NASDAQ:ADXS) opened at $3.14 on Thursday. Advaxis, Inc. has a one year low of $2.83 and a one year high of $10.06.
Advaxis (NASDAQ:ADXS) last posted its quarterly earnings data on Monday, September 11th. The biotechnology company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.27). The firm had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $3.43 million. Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. equities research analysts expect that Advaxis, Inc. will post -2.21 earnings per share for the current fiscal year.
In other Advaxis news, major shareholder Adage Capital Partners Gp, L.L sold 1,239,323 shares of the stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $4.42, for a total value of $5,477,807.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert Petit sold 12,625 shares of the stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total transaction of $40,273.75. Following the completion of the sale, the insider now owns 237,265 shares of the company’s stock, valued at approximately $756,875.35. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,872,291 shares of company stock valued at $8,163,810. Company insiders own 7.21% of the company’s stock.
ADXS has been the topic of several recent research reports. BidaskClub cut shares of Advaxis from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. ValuEngine cut shares of Advaxis from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price target on shares of Advaxis in a research report on Friday, September 15th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $19.00 price objective on shares of Advaxis in a research note on Monday, September 25th.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://sportsperspectives.com/2017/11/23/new-york-state-common-retirement-fund-sells-1-shares-of-advaxis-inc-adxs.html.
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.